etanidazole
PreclinicalSmall molecule
etanidazole is one of 33 small molecule programs targeting Malignant Glioma. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
34 competitors in Malignant Glioma
#DrugCompanyPhaseTrials
1Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Norvir
AbbVieApproved
Lynparza
AstraZenecaApproved
Levulan
Sun Pharmaceutical Industries, Inc.Approved
Plaquenil
Jazz PharmaceuticalsApproved
Ziagen
GSKApproved
Afinitor
NovartisApproved
Tafinlar
NovartisApproved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Advil
KKenvue Brands
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Malignant Glioma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for etanidazole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- NNational Cancer Institute (NCI)